Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

西妥昔单抗 医学 福克斯 内科学 结直肠癌 肿瘤科 养生 人口 化疗方案 化疗 外科 奥沙利铂 癌症 环境卫生
作者
De‐Shen Wang,Chao Ren,Shanshan Li,William Pat Fong,Xiaojun Wu,Jian Xiao,Binkui Li,Yun Zheng,Peirong Ding,Gong Chen,Miao‐Zhen Qiu,Zhi‐Qiang Wang,Feng‐Hua Wang,Hui Luo,Rui Wang,Xiaozhong Wang,Lingling Wang,De-Jin Xie,Tao Chen,Li Li
出处
期刊:PLOS Medicine [Public Library of Science]
卷期号:21 (5): e1004389-e1004389 被引量:4
标识
DOI:10.1371/journal.pmed.1004389
摘要

Background It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. Methods and findings This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI ( n = 72) or cetuximab plus FOLFOX ( n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus ≥5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann–Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade ≥ 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade ≥ 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. Conclusions The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. Trial Registration ClinicalTrials.gov Identifier: NCT03493048 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐应助忐忑的阑香采纳,获得10
2秒前
哈哈完成签到,获得积分10
2秒前
苏su关注了科研通微信公众号
2秒前
少主发布了新的文献求助10
2秒前
3秒前
3秒前
4秒前
安静发布了新的文献求助10
5秒前
上官若男应助PANYIAO采纳,获得10
6秒前
9秒前
tingting9发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
Akim应助高手采纳,获得10
10秒前
10秒前
李健的小迷弟应助ZZZ采纳,获得10
10秒前
你好呀嘻嘻完成签到 ,获得积分10
10秒前
zwxzghgz完成签到,获得积分10
11秒前
hello发布了新的文献求助10
15秒前
15秒前
15秒前
15秒前
crazy完成签到,获得积分10
16秒前
咩咩羊发布了新的文献求助10
17秒前
易儿发布了新的文献求助10
17秒前
PANYIAO发布了新的文献求助10
18秒前
李彪完成签到,获得积分20
18秒前
小柒完成签到,获得积分10
19秒前
Lucas应助13223456采纳,获得10
20秒前
22秒前
chris发布了新的文献求助50
22秒前
简单面包完成签到,获得积分10
25秒前
踏实的老四完成签到,获得积分20
25秒前
27秒前
洪汉发布了新的文献求助50
29秒前
30秒前
31秒前
hahahah发布了新的文献求助20
32秒前
Hello应助猪猪hero采纳,获得10
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136